Key Points Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, Recursion will face significant challenges that could sink its share price. 10 stocks we like better than Recursion Pharmaceuticals › Recursion Pharmaceuticals (NASDAQ: RXRX), a biotech focused on artificial intelligence (AI), became a publicly traded company in 2021 -- a time when AI did n ...

It's unclear how long it's going to be before this company has a product to sell.The artificial intelligence (AI) revolution has the potential to alter just about every business operation for the better. One area where investors are extra excited about productivity improvements is the drug development business.The vast majority of experimental drugs that enter clinical trials never become marketable products, but by applying AI to the discovery process, Recursion Pharmaceuticals (RXRX 1.84%) plans to become ...

On CNBC's “Mad Money Lightning Round,” Jim Cramer said he likes Dutch Bros (NYSE: BROS). He recommended buying some now and then buying some of the stock in the $40s.On Sept. 24, RBC Capital analyst Logan Reich reiterated Dutch Bros with an Outperform and maintained a price target of $85.American Bitcoin Corp (NASDAQ: ABTC) is a “total spec,” Cramer said.As per the recent news, American Bitcoin, on Thursday, named KPMG as new auditor.Recursion Pharmaceuticals (NASDAQ: RXRX) has been a “bad stock. We need to ...

On CNBC's “Mad Money Lightning Round,” Jim Cramer said he likes Dutch Bros (NYSE: BROS). He recommended buying some now and then buying some of the stock in the $40s.On Sept. 24, RBC Capital analyst Logan Reich reiterated Dutch Bros with an Outperform and maintained a price target of $85.American Bitcoin Corp (NASDAQ: ABTC) is a “total spec,” Cramer said.As per the recent news, American Bitcoin, on Thursday, named KPMG as new auditor.Recursion Pharmaceuticals (NASDAQ: RXRX) has been a “bad stock. We need to ...

BigBear.ai is bigger than both of these AI-focused companies now. That could change.BigBear.ai (BBAI -6.00%) has taken investors on a rollercoaster ride in 2025. The good news, though, is that they're probably enjoying the ride these days. Shares of the artificial intelligence (AI) software company are up more than 70% year to date.Will BigBear.ai's momentum continue? Maybe. However, I think investors can do better. I predict that two stocks will be worth more than BigBear.ai five years from now. 1. Diebold ...

It’s a sign that’s impossible to ignore. As you soon as you pull up the Price Overview for Recursion Pharmaceuticals (RXRX), you’re greeted with a clear message: Barchart’s Technical Opinion indicator rates RXRX stock as a 72% Strong Sell. From an empirical perspective, suggesting a contrarian position would place you on shaky ground. Since the start of the year, RXRX stock is down nearly 28%, which in many respects is understandable given the uncertainties associated with the broader healthcare ecosystem ...

In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Recursion Pharmaceuticals, Inc. is one of them. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), a clinical-stage biotech, is pioneering the use of artificial intelligence and machine learning to accelerate drug discovery, with a focus on rare diseases and oncology. Its proprietary Recursion OS combines high-throughput biology and multimodal datasets to streamline therapeutic development. In September 2025, Recurs ...

公司评级与目标价 - Needham维持Recursion Pharmaceuticals买入评级 目标价8美元 较当前4.77美元有68%上行空间[1] - 摩根士丹利和美国银行维持持有评级 目标价分别为4.8美元和8美元[3] - 华尔街分析师平均目标价为6.5美元 隐含34.58%上涨空间[3] 公司核心优势 - 拥有AI驱动的Recursion OS操作系统 整合高通量生物实验、成像与机器学习技术[4][5] - 通过收购Cyclica和Valence强化生物化学大模型与AI算力能力[5] - 专有数据集覆盖数万亿级生物化学关系 处于行业领先地位[1][4] 财务状况与管线进展 - 现金可支撑运营至2027年第四季度[2] - 核心管线REC-617（CDK7抑制剂）处于实体瘤I/II期阶段[5] - REC-1245（RBM39降解剂）针对实体瘤和淋巴瘤处于I/II期[5] 行业前景 - AI医疗保健市场规模将从2022年104亿美元增长至2030年1899亿美元 年复合增速43.7%[7] - 生成式AI在药物发现、基因编辑、医疗诊断等领域取得突破性进展[6] - 英伟达CEO黄仁勋称AI+医药是"下一场技术革命"[6] 机构背书 - Needham曾成功挖掘Tempus AI、Axsome Therapeutics等生物科技牛股[2] - Recursion被列为"华尔街对冲基金最看好的12只纳斯达克便士股之一"[1] - 公司通过行业会议和论坛持续整合买方/卖方资源[2]

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the 12 Best NASDAQ Penny Stocks to Buy According to Hedge Funds. On September 10, Needham retained its Buy rating on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), maintaining the price target at $8. Gil Blum from Needham reaffirmed the rating on RXRX due to various factors, pointing out the company’s strong position in the AI-driven drug discovery sector. Being a leader in this space, the company is backed by its extensive and proprietary dataset. ...

会议介绍 - 摩根士丹利举办全球医疗健康会议 由美国中型生物科技股票研究主管Sean Laaman主持[1] - 会议设置研究披露网站为www morganstanley com/researchdisclosures[1] 参会人员 - Recursion公司参会高管包括联合创始人兼首席执行官Chris Gibson 首席研发官兼首席商务官Najat Khan[2] - 公司首席财务官未出席本次会议环节[2]